Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sanofi (SNY) Total Debt (2016 - 2025)

Sanofi's Total Debt history spans 17 years, with the latest figure at $21.6 billion for Q4 2025.

  • On a quarterly basis, Total Debt rose 26.57% to $21.6 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $21.6 billion, a 26.57% increase, with the full-year FY2025 number at $21.6 billion, up 26.57% from a year prior.
  • Total Debt hit $21.6 billion in Q4 2025 for Sanofi, down from $23.2 billion in the prior quarter.
  • Over the last five years, Total Debt for SNY hit a ceiling of $24.3 billion in Q2 2021 and a floor of $17.1 billion in Q4 2024.
  • Historically, Total Debt has averaged $21.1 billion across 5 years, with a median of $21.1 billion in 2023.
  • Biggest five-year swings in Total Debt: dropped 16.47% in 2022 and later grew 26.57% in 2025.
  • Tracing SNY's Total Debt over 5 years: stood at $23.2 billion in 2021, then fell by 16.42% to $19.4 billion in 2022, then dropped by 9.17% to $17.6 billion in 2023, then fell by 3.06% to $17.1 billion in 2024, then rose by 26.57% to $21.6 billion in 2025.
  • Business Quant data shows Total Debt for SNY at $21.6 billion in Q4 2025, $23.2 billion in Q2 2025, and $17.1 billion in Q4 2024.